R&D News | pharmaphorum

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

News

Obesity biotech Kailera's record-breaking IPO

When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.

News

OpenAI introduces GPT-Rosalind, its drug discovery AI

In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.

News

UK says it has hit target on commercial trial set-up times

The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.

News

Lift for UK healthtech as fund bags £100m from national bank

A new Apposite Capital fund has been set up with £100m to provide much-needed scale-up funding for UK biopharma and healthtech companies.

News

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

Obesity biotech Kailera's record-breaking IPO

OpenAI introduces GPT-Rosalind, its drug discovery AI

UK says it has hit target on commercial trial set-up times

Lift for UK healthtech as fund bags £100m from national bank

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks